Is NVAX or OABI more undervalued in 2026?

CirclFi compares Novavax, Inc. (NVAX) and OmniAb, Inc. (OABI) using 13 institutional-grade valuation models. NVAX has a Quality of Company score of 6.4/10 while OABI scores 5.8/10.

Which is a better buy — NVAX or OABI?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do NVAX and OABI valuations compare?

NVAX at $10.32 and OABI at $2.72 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

NVAX vs OABI Valuation Comparison 2026 — Intrinsic Value Analysis

NVAX

Biotechnology

Novavax, Inc.

Quality

6.4

out of 10

Value Trap

SAFE

Price

$10.32

Last close

Models

11/13

Active

OABI

Biotechnology

OmniAb, Inc.

Quality

5.8

out of 10

Value Trap

LOW

Price

$2.72

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	NVAX Fair Value	NVAX Upside	OABI Fair Value	OABI Upside
Bayesian DCF	Intrinsic	$1.55	-84.9%	$0.58	-78.7%
Earnings Power Value	Intrinsic	$2.46	-69.6%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$4.46	-56.8%	$0.45	-83.5%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for NVAX vs OABI — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NVAX vs OABI — Which Stock Is More Undervalued?

NVAX scores higher with a 6.4/10 quality rating vs OABI's 5.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Novavax, Inc. (NVAX) and OmniAb, Inc. (OABI) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NVAX currently trades at $10.32 with a QOC of 6.4/10, while OABI trades at $2.72 with a QOC of 5.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).